D-Trp-Aib
D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a Kd of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1123071-24-8
- Fòrmula: C15H19N3O3
- Peso molecular:289.34
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas α-synuclein
More
Actividad biológica
D-Trp-Aib (Compound 1) binds to Aβ1-42 with an Kd of 29.6 ± 1.7 nM[1].
D-Trp-Aib triggers the formation of larger, non-toxic amorphous and globular clusters from Aβ1-42[1].
D-Trp-Aib partially prevents Aβ1-42-induced membrane potential depolarization[1].
D-Trp-Aib (0.1 nM-1 μM; 90 min) reverses Aβ1-42-induced LTP deficits in mouse hippocampal slices[1].
D-Trp-Aib (molar ratio 1:10-1:30, 50 h) inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin, and disassembles preformed amyloid fibrils[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
D-Trp-Aib (0.5-2.0%; eye drops; three times daily; 1 month) reduces toxic amyloid β1-42 deposits and associated complement component C3b inflammation in the retina of an aged AMD mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (5-6 months old; age-related macular degeneration genetic model)[1]
-
Dosage:0.5%; 2.0%
-
Administration:eye drops; three times daily; 3 months
-
Result:Caused a significant reduction in retinal amyloid β1-42 levels compared to vehicle-treated mice.
Produced a greater reduction in retinal amyloid β1-42 levels at 2.0% dose than at 0.5% dose.
-
Animal Model:C57BL/6 (24 months old; aged age-related macular degeneration model)[1]
-
Dosage:0.5%; 2.0%
-
Administration:eye drops; three times daily; 1 month
-
Result:Reduced thick, linear amyloid β1-42 deposits along the Bruch's membrane to isolated, non-toxic aggregates, with no amyloid β1-42 staining in the retinal pigment epithelium.
Induced a corresponding colocalized reduction in C3b (a marker of amyloid β-induced inflammation) compared to controls.
Chemical Information
-
No. CAS 1123071-24-8
-
Peso molecular 289.34
-
Fòrmula C15H19N3O3
-
SMILES
C([C@H](C(NC(C(O)=O)(C)C)=O)N)C=1C=2C(NC1)=CC=CC2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
D-Trp-Aib Related Classifications
HY-114613 Related Classifications
Powered by Bioz